Valuation Mesoblast Limited OTC Markets

Stocks

Market Closed - OTC Markets 10:51:57 2026-08-10 EDT			5-day change	1st Jan Change
1.890 ^USD	+11.18%		0.00%	-0.53%

08-17	Mesoblast Limited Completes Patient Treatment In Pivotal Phase 3 Trial Of Rexlemestrocel-L For Chronic Low Back Pain	CI
08-17	Mesoblast Completes Patient Treatment in Phase 3 Trial of Chronic Low Back Pain	MT

Data adjusted to current consolidation scope

Fiscal Period: June	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	1,282	396.4	923.5	1,130	2,114	3,263	-	-
Change	-	-69.07%	132.95%	22.34%	87.09%	54.37%	-	-
Enterprise Value (EV) ¹	1,239	396.4	981.2	1,206	2,053	3,240	3,159	2,786
Change	-	-68%	147.49%	22.87%	70.3%	57.82%	-2.5%	-11.8%
P/E	-4.42x	-1.49x	-3.33x	-7.54x	-12.8x	-40x	92.3x	10.5x
PBR	-	-	0.6x	1.6x	2.18x	4.39x	4.39x	4.39x
PEG	-	0.17x	0.2x	0.1x	9.95x	0.8x	-1x	0x
Capitalization / Revenue	125x	26.7x	80x	130x	80.2x	18x	10.6x	5.52x
EV / Revenue	121x	26.7x	84.9x	139x	77.9x	17.9x	10.2x	4.71x
EV / EBITDA	-10.7x	-3.9x	-11x	-13.5x	-18.5x	-106x	-114x	130x
EV / EBIT	-10.2x	-3.67x	-10.3x	-12.6x	-17x	-54.3x	62.2x	9.61x
EV / FCF	-8.36x	-4.14x	-10x	-16.8x	-26.5x	-295x	44.3x	13.5x
FCF Yield	-12%	-24.2%	-9.97%	-5.96%	-3.78%	-0.34%	2.26%	7.41%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-0.4476	-0.4091	-0.3412	-0.1313	-0.1296	-0.0627	0.0272	0.239
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	10.22	14.84	11.55	8.7	26.36	180.9	308.6	591.2
EBITDA ¹	-115.9	-101.6	-89.11	-89.14	-111	-30.63	-27.79	21.45
EBIT ¹	-121.9	-107.9	-95.44	-96.02	-120.8	-59.71	50.8	290.1
Net income ¹	-135.4	-132.7	-126.1	-129.7	-156.5	-77.32	29.01	236.3
Net Debt ¹	-42.95	-	57.66	75.75	-60.77	-22.87	-103.9	-476.7
Reference price ²	1.980	0.610	1.135	0.990	1.655	2.510	2.510	2.510
Nbr of stocks (in thousands)	647,399	649,912	813,662	1,141,241	1,277,239	1,300,009	-	-
Announcement Date	8/30/21	8/30/22	8/30/23	8/28/24	8/28/25	-	-	-

¹AUD in Million²AUD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
LONZA GROUP AG	34.4x	6.13x	18.24x	0.93%	51.22B
REVOLUTION MEDICINES, INC.	-21.71x	301.09x	-22.35x	-.--%	45.38B
BEONE MEDICINES AG	48.36x	5.61x	30.68x	-.--%	41.97B
IQVIA HOLDINGS INC.	32.97x	3.21x	13.87x	-.--%	42.15B
CELLTRION, INC.	29.48x	8.52x	21.54x	0.39%	31.95B
MEDPACE HOLDINGS, INC.	34.84x	5.71x	25.97x	-.--%	17.1B
EUROFINS SCIENTIFIC SE	24.28x	2.11x	9.12x	1.11%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	77.97x	4.1x	15.89x	-.--%	13.91B
Average	32.57x	42.06x	14.12x	0.3%	32.31B
Weighted average by Cap.	27.77x	57.29x	12.69x	0.3%